CASI Pharmaceuticals (CASIF) Equity Income (2023 - 2025)
CASI Pharmaceuticals (CASIF) reported Equity Income of -$2.4 million for Q4 2025, down 183.93% on a YoY basis from $2.8 million in Q4 2024, and down 154.19% quarter-over-quarter from $4.4 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Equity Income (2023 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported Equity Income for 3 years, with the latest figure at -$2.4 million in Q4 2025.
- For the quarter ending Q4 2025, Equity Income fell 183.93% year-over-year to -$2.4 million; the trailing twelve-month figure through Dec 2025 stood at -$448000.0 (down 129.4% YoY), and the FY2025 full-year result was -$179000.0, down 110.55% from the prior year.
- Equity Income for Q4 2025 stood at -$2.4 million, down from $4.4 million in the prior quarter.
- The five-year high for Equity Income was $4.4 million in Q3 2025, with the low at -$2.4 million in Q4 2025.
- Historically, Equity Income has averaged $82363.6 across 3 years, with a median of -$140000.0 in 2023.
- The largest YoY upside for Equity Income was 281300.0% in 2024 against a maximum downside of 7340.0% in 2024.
- CASI Pharmaceuticals' Equity Income stood at -$1000.0 in 2023, then soared by 281300.0% to $2.8 million in 2024, then slumped by 183.93% to -$2.4 million in 2025.
- The last three Equity Income figures came in at -$2.4 million (Q4 2025), $4.4 million (Q3 2025), and -$2.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | - |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | -2.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.36 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Jun 30, 2025 | -2.17 Mn |
| Mar 31, 2025 | -269,000.00 |
| Dec 31, 2024 | 2.81 Mn |
| Sep 30, 2024 | -1.12 Mn |
| Mar 31, 2024 | -171,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -15,000.00 |
| Mar 31, 2023 | -140,000.00 |